MedTrace Logo

GDNF Gene Therapy for Parkinson's Disease

NCT04167540 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2025-09-19

No results posted yet for this study

Summary

The objective of this Phase 1b investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a recent or a long-standing diagnosis of PD.

Conditions

Interventions

BIOLOGICAL

AAV2-GDNF

Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose

Sponsors & Collaborators

  • AskBio Inc

    collaborator INDUSTRY

  • California Institute for Regenerative Medicine (CIRM)

    collaborator OTHER

  • Brain Neurotherapy Bio, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2023-10-17
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04167540 on ClinicalTrials.gov